The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app
It’s all too easy for pharmaceutical processes to slow marketing campaigns, rendering them unmanageable and ineffective, but a ground-breaking initiative is proving that digital content del
As part of a series of articles highlighting the role of women in the pharma industry, Richard Staines speaks to Louise Houson, MSD’s managing director for UK and Ireland
MSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma or adenocarcinoma who progressed after standard therapy.